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Objectives: To characterize treatment patterns and survival outcomes for patients
with locally advanced or metastatic malignancy of the urothelial tract during a period
immediately preceding the widespread use of immune checkpoint inhibitors in the UK.
Patients and Methods: We retrospectively examined the electronic case notes of
patients attending the Leeds Cancer Center, UK with locally advanced or metastatic
urothelial carcinoma, receiving chemotherapy between January 2003 and March 2017.
Patient characteristics, treatment patterns, and outcomes were collected. Summary
and descriptive statistics were calculated for categorical and continuous variables as
appropriate. The Kaplan–Meier method was used to estimate median survival and Cox
regression proportional hazards model was used to explore relationships between clinical
variables and outcome.
Results: Two hundred and sixteen patients made up the study cohort, with a median
age of 66 years (range: 35–83) and 72.7% being male. First-line treatment consisted
of either a cisplatin- (44%) or carboplatin-based regimen (48%) in the majority of
patients. Twenty seven percent of patients received a second-line of treatment (most
commonly single-agent paclitaxel) following a first-line platinum containing regimen.
Grade 4 neutropenia was observed in 19 and 27% of those treated with a first-line
cisplatin- and carboplatin-based regimen, respectively. The median overall survival (mOS)
of the study cohort was estimated to be 16.2 months (IQR: 10.6–28.3 months). Receipt
by patients of cisplatin-based chemotherapy was associated with a longer mOS and
this association persisted when survival analysis was adjusted for age, sex, performance
status and presence of distant metastases.
Conclusions: This study provides a useful benchmark for outcomes achieved in
a real-world setting for patients with locally advanced or metastatic UC treated with
chemotherapy in the immediate pre-immunotherapy era.
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INTRODUCTION
Malignant neoplasms of the urinary tract include cancers of the
bladder, renal pelvis, ureter and urethra, but are increasingly
recognized as a single site in international coding schemes
when diagnosed at the same time (1). The majority of patients
diagnosed with these malignancies have urothelial cancer (UC)
(also known as transitional cell carcinoma), but rarer types are
also recognized, such as squamous cancers, adenocarcinomas,
and neuroendocrine tumors. The most common site, bladder
cancer, is the ninth most common cancer overall in the UK and
the sixth most common in men (2). Recognized risk-factors for
the development of bladder cancers include tobacco smoking,
chemical exposure and chronic urinary tract infections (3).
In 2014,∼25% of patients with bladder cancer in England had
locally advanced or metastatic disease at the time of presentation
(4). Internationally, platinum-based chemotherapy has formed
the standard of care for such patients at first-line for more than
three decades (5–7). Current European Association of Urology
guidance estimates 50% of patients with UC are not sufficiently
fit to tolerate cisplatin-based therapy (8). Carboplatin-based
regimens represent an alternative first-line treatment for those
with poor renal function or poor performance status (PS).
However, outcomes with carboplatin are recognized to be less
favorable (7). Second-line treatment options are limited and no
standard of care has been established, with paclitaxel, docetaxel,
and vinflunine all variably employed. Vinflunine is not currently
approved for use in the UK (9).
With the recent introduction of checkpoint inhibitors (CPI)
targeting programmed cell death protein-1 or its ligand (PD-
1/PD-L1), the treatment landscape for patients with metastatic
UC (mUC) has been transformed. In the first-line setting,
immunotherapy now forms a new standard of care in patients
who are ineligible for cisplatin and whose tumors express PD-
L1 (10, 11). In the second-line setting, following platinum-
failure, pembrolizumab has been shown to increase overall
survival in comparison to existing treatment options (12). Studies
examining first-line combination anti-PD1/PDL-1 plus cytotoxic
T-lymphocyte-associated antigen-4 (CTLA-4) are also underway
(13) that may further alter the therapeutic pathway.
Despite treatment, prognosis is generally poor for patients
with metastatic disease; median survival between 15 and 18
months is reported in clinical trials (14). However, non-
concordance between clinical trials and real-world practice is
well-recognized (15) and there is little published information
on real-world outcomes for patients with locally advanced
or metastatic UC in the UK. As the treatment landscape
changes, gaining a fuller understanding of current clinical
practice and patient outcomes sets an important benchmark
against which the real-world impact of novel therapies can
be evaluated.
The aim of this study was to characterize the existing
population of patients treated within a large regional cancer
center with such malignancies in the period immediately
preceding the introduction of CPI into routine clinical practice.
Study objectives included defining the baseline demographic and
clinical characteristics of patients at first presentation, describing
treatments received, summarizing survival, and quantifying the
incidence of selected adverse events.
PATIENTS AND METHODS
Study Design
This study was conducted using a retrospective longitudinal
cohort design, with secondary use of electronic medical records
data. Eligible patients were identified from a major regional
NHS cancer center in the UK between January 2003 and
March 2017 and followed-up from first presentation (index date)
until February 2018 to observe survival outcomes and selected
adverse effects.
Setting
The Leeds Cancer Center (LCC) serves a metropolitan catchment
area of over 850,000 people for secondary care and 2.7
million as a regional cancer center. LCC is hosted by Leeds
Teaching Hospitals NHS Trust (LTHT). Patient data including
all demographics, cancer diagnoses and staging and anti-cancer
therapy are managed in patient pathway manager (PPM), an in
house LTHT EMR developed and brought into routine clinical
use in 2003.
This study was conducted by the Real-world Evidence Alliance
Leeds (REAL), a collaboration between LCC, Leeds Institute
for Data Analytics and IQVIATM. REAL accesses continually
updated patient data stored in PPM and unstructured data within
patient notes was additionally reviewed by a consultant medical
oncologist both to maximize data completeness and to enable
derivation of outcome variables. REAL studies are conducted on-
site within LTHT under the strict legal framework governing
access to and use of personal information in the NHS (16). The
study was completed with UK Health Research Authority formal
approval; the need for ethics approval was waived.
Participants
Eligible patients for inclusion were those adult patients (≥18
years old) with a confirmed incident diagnosis of advanced
or metastatic malignancy of the urothelial tract and recorded
treatment with chemotherapy between January 2003 and
March 2017. Advanced or mUC was defined according to
the appropriate International Classification of Disease (ICD)-
10 codes (C65–C68) and tumor, nodes and metastasis (TNM)
staging (T4b, N0, M0, or Tany, N1-3, M0, or Tany, Nany, M1).
Patients were excluded if any one or more of the following
applied: incomplete treatment records (e.g., where an incident
diagnosis was made in a center outside the scope of LCC);
periods of early treatment were missing; incomplete TNM
staging; significant other malignancies were present; and/or
tumor morphology other than urothelial carcinoma.
Data Variables
For this study, total person-time was defined by diagnosis index
date (first diagnosis of locally advanced or mUC) or treatment
index date (date of first treatment), censor date (if lost to follow-
up) or end of study period (February 2018).
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Unless otherwise stated, patient and clinical characteristics
were as recorded in PPM at diagnosis index date or the
date closest to (and following) index date. Smoking status
was not well recorded in PPM and therefore extracted from
unstructured patient notes during the process of clinical review.
Performance status (PS) was as defined by the World Health
Organization or Eastern Cooperative Oncology Group (ECOG)
scheme (17). TNM staging followed the Union for Cancer
Control (UICC)/American Joint Committee on Cancer (AJCC)
TNM classification (7th edition) (18). Morphology was defined
in accordance with ICD-10- morphology codes and the study
cohort included patients with transitional cell carcinomas
(ICD10 code M8120/0-3).
Treatment was reported by line of therapy and regimen—
all regimens of chemotherapy recorded in PPM were reported.
Treatment with radiotherapy was reported by treatment intent.
Line of therapy was designated as treatment following index date
and sequential line of therapy derived during review of clinical
notes. Treatment duration and time between treatments was
defined according to respective start and end dates of line of
therapy. Surgical treatment was not collected.
Summary and descriptive statistics were calculated for
categorical and continuous variables as appropriate.
Patient Outcomes
Tumor response to treatment was derived from radiology reports
recorded in PPM by the treating clinician using variables
“complete response,” “partial response,” “stable disease,” or
“progressive disease.” Response was not further reviewed or
confirmed for the study. Overall Survival (OS) was defined
as time since index date until date of death due to any
cause. Confirmed date of death was used, following monthly
reconciliation of PPM with Office for National Statistics death
certifications. Patients without any record of death during
the study period were censored accordingly. Progression Free
Survival (PFS) was defined as time since index date until the
first disease progression date. Patients without any record of
disease progression during the study period were censored
accordingly. Overall response rate (ORR) was defined as the
proportion of patients in a particular sub-group experiencing a
complete or partial response following treatment. Disease control
rate (DCR) was defined as the proportion of patients in a
particular sub-group experiencing an overall response (as above)
or stable disease.
Data Analysis
Summary statistics were calculated for the demographic and
treatment pattern characteristics of patients within the final
evaluable cohort. Continuous variables were described by the
mean, standard deviation, median, 25th and 75th percentiles,
minimum and maximum. Categorical variables were described
by the number and percentage of patients in each category.
Differences between categorical variables were tested using
Pearson χ2 test, and differences between continuous variables
tested by using parametric two sample t-tests, where appropriate.
OS from index date (diagnosis or treatment as appropriate)
were estimated using the Kaplan Meier survival methodology
and depicted graphically by Kaplan-Meier curves, with number
of at-risk patients at particular time-points tabulated below
the curves. Censored patients are indicated graphically. Median
OS was reported, including 25th and 75th percentiles. A Cox
proportional hazards regression analysis was also conducted
to calculate adjusted hazard ratios (HR) with 95% confidence
intervals (95% CI) for identified predictor variables. Model
diagnostics assessed the robustness of the model.
RESULTS
Patient Characteristics
Of 483 patients identified, 199 were excluded based on TNM
staging and a further 68 were excluded based on treatment
record or other exclusion criteria. The study cohort consisted of
216 patients, diagnosed with advanced or metastatic urothelial
carcinoma between 2003 and 2017. Summary characteristics of
the evaluable cohort are shown in Table 1. The study cohort
was 72.7% male with a median age of 66 years (IQR: 59–72
years; range: 35–83 years). The most common primary tumor
site was in the bladder (77.3%; n = 167) with ureter or renal
pelvis accounting for almost all others (20.8%; n = 45). Where
TABLE 1 | Patient Characteristics of study cohort.
Patient characteristic (% all) Study cohort (N = 216)
Male 157 (72.7%)
Age Median (IQR)
Mean (SD)
66 (59,72)
65.0 (9.4)
Tumor site Bladder 167 (77.3%)
Ureter 31 (14.4%)
Renal pelvis 14 (6.5%)
Urethra <6
TNM at index T4b,N0,M0 6 (2.8%)
Tany,N1-3,M0 87 (40.3%)
Tany,Nany,M1 123 (56.9%)
Smoking status Current smoker 57 (26.4%)
Ex-smoker 93 (43.1%)
Never smoked 18 (8.3%)
Non-smoker (history
unknown)
26 (12.0%)
Smoking status NK 22 (10.2%)
ECOGa 0 66 (30.6%)
1 77 (35.6%)
2 24 (11.1%)
3 <6
NK 48 (22.2%)
BMIb Mean (SD) 26.54 (4.73)
<25 83 (38.4%)
25–29.9 84 (38.9%)
30+ 47 (21.8%)
aECOG recorded for patients at the first point of receiving treatment with chemotherapy
following index date.
bBody mass index: measures of 25 and above are considered to exceed healthy weight,
with 30 being the threshold for obesity in the UK (19). Data was missing for 2 patients.
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smoking status was recorded (n = 194), the majority were ex-
smokers (43.1%; n = 93) or current smokers (26.4%; n = 57).
Over a third of patients had a BMI status below 25 kg/m2 (38.4%;
n = 83). Where ECOG PS was reported (n = 168), 85.1% (n =
143) had a score <2. Over half of the study cohort (56.9%, n =
123) had distantmetastases (M1) at index date, themost common
sites being lymph nodes (31.0%; n= 67), pulmonary (15.3%; n=
33), and bone (14.8%; n= 32).
First-line Treatment Patterns
In addition to receiving systemic treatment at least once
following index date, 44.9% (n = 97) of patients in the study
cohort also received radiotherapy. The majority of patients
receiving radiotherapy (75%; n = 73) were treated with
palliative intent, but 24 (24.7%) were treated with radical
radiotherapy, either in addition to or instead of palliative
treatment. Cisplatin/gemcitabine and carboplatin/gemcitabine
were themost commonly received chemotherapy regimens at any
point following index date [41.7% (n = 90) and 40.7% (n = 88),
respectively] but patients also received a range of other platinum-
and non-platinum-based therapies (Table 2).
At first-line of treatment, 44.4% (n = 96) of patients were
treated with a cisplatin-based regimen (“cisplatin sub-cohort”),
48.1% (n = 104) with a carboplatin-based regimen (“carboplatin
sub-cohort”) and 5.1% (n = 11) with a non-platinum single
agent (either paclitaxel or gemcitabine) (“non-platinum sub-
cohort”). No patients in the non-platinum sub-cohort were
diagnosed or first treated later than 2010. The remaining patients
were treated at first-line with therapies generally used for small
cell disease or experimental regimens and are not included in
subsequent analysis. There was a small number of patients (<6)
who were started on cisplatin-based chemotherapy but switched
to carboplatin during the first-line of therapy and these are
included in the cisplatin-based sub-cohort.
Where baseline characteristic data were stratified by platinum
regimen treatment type, there was no difference in the
TABLE 2 | Treatment regimens at any time throughout study (all lines of therapy).
Chemotherapy
category
Regimen Study cohort (N = 216)
Cisplatin-based Cisplatin/gemcitabine 90 (41.7%)
Accelerated MVACa 7 (3.2%)
Gemcitabine/cisplatin/sunitinib <6
Carboplatin—based Carboplatin/gemcitabine 88 (40.7%)
Carboplatin MVb 27 (12.5%)
Carboplatin/gemcitabine
(TOUCAN trial)
9 (4.2%)
Carboplatin/paclitaxel 8 (3.7%)
Non-platinum Gemcitabine 13 (6.0%)
Paclitaxel 32 (14.8%)
Otherc Carboplatin/etoposide 6 (2.8%)
CAVd <6
aMVAC, Methotrexate/vinblastine/doxorubicin/cisplatin.
bMV, Methotrexate/vinblastine.
cOther therapies include treatments for small cell carcinoma UC.
dCAV, Cyclophosphamide/doxorubicin/vincristine.
distribution of sex, smoking status, or tumor site (Table 3).
Patients within the cisplatin sub-cohort were younger and
more likely to have a BMI below 25 kg/m2 than those in the
carboplatin sub-cohort. Patients within the carboplatin sub-
cohort were more likely to have a PS of at least 2 and to
have metastatic disease at index date than those in the cisplatin
sub-cohort. The distribution of distant metastases sites was
similar between the two sub-cohorts, with metastases of lymph
nodes most commonly recorded. Patients in the non-platinum
sub-cohort were older (median 72, range 69–83) and more
likely to have PS of at least 2 (data not shown). Response
rates to chemotherapy, overall and by first-line regimen, are
shown in Table 4. Patients in the cisplatin sub-cohort were
more likely than the carboplatin sub-cohort to have a complete
response [χ2, df (1), p = 0.03] and less likely to have progressive
disease [χ2, df (1), p < 0.01].
Second-line Treatment Patterns
Following treatment with a first-line platinum-based regimen
(n = 200), 26.5% (n = 53) of patients progressed to a second-
line treatment. For patients in the cisplatin sub-cohort, 30.2% of
patients (n= 29) progressed to second-line treatment, compared
with 23.1% of patients (n = 24) in the carboplatin sub-cohort,
but this difference was not statistically significant [χ2, df (1), p
= 0.25]. Of the 147 treated with platinum but not progressing
to a second-line therapy before study end, 17.7% (n = 26) died
during treatment and patients on first-line carboplatin weremore
likely to die during treatment than those on cisplatin [χ2, df (1),
p= 0.04].
Non-platinum containing regimens were used second-line for
62.3% (n = 33), most commonly single-agent paclitaxel (43.4%;
n = 23) or gemcitabine (13.2%; n = 7). Carboplatin-based
regimens were used for 30.2% (n = 16) of these patients second-
line. The ratio of use of these regimens was similar between
the platinum sub-cohorts (Figure 1). For a small proportion of
patients treated with first-line cisplatin, a further cisplatin-based
regimen was used second-line. Of all patients treated with first-
line platinum agents (n= 200), 5.5% (n= 11) went on to receive
at least a third-line of chemotherapy.
The duration of first-line treatment was similar between the
two sub-cohorts; median 126 days (IQR: 78,156, range 21–936)
for patients receiving cisplatin-based regimens and median 126
days (IQR: 84,143, range 21–828) for those receiving carboplatin.
Median duration of second-line chemotherapy was 78 days (IQR:
45,116, range 21–168) for the cisplatin sub-cohort and 120 days
(IQR: 100,137, range 21–644) for the carboplatin sub-cohort.
The median time between the end of first-line and beginning of
second-line was 235 days (IQR: 142,283, range 22–1,102) for the
cisplatin sub-cohort and 172 days (IQR: 126,219, range 21–476)
for the carboplatin sub-cohort.
No patients receiving non-platinum regimens as first-line
treatment received subsequent second-line chemotherapy, but
a small number were subsequently treated with palliative
radiotherapy (data not shown).
Survival Outcomes
Median overall survival (mOS) of the study cohort (n = 216)
was estimated to be 16.2 months (IQR: 10.6, 28.3 months).
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TABLE 3 | Characteristics of patients treated with a first-line platinum-based agent following index date, by regimen type.
Patient characteristic (% sub-cohort) Cisplatin sub-cohort (N = 96) Carboplatin sub-cohort (N = 104) Test of difference between
sub-cohorts
Male 76 (79.2%) 72 (69.2%) χ2 df (1), p = 0.15
Age Median (IQR)
Mean (SD)
63 (56,68)
61.2 (8.66)
69 (62,74)
67.9 (8.42)
t-test, p < 0.01
Tumor site Bladder 77 (80.2%) 76 (73.0%) χ2 df (1), p = 0.25d
Ureter 11 (11.5%) 19 (18.3%)
Renal pelvis <6 8 (7.7%)
Urethra <6 <6
TNM at index T4b,N0,M0 <6 <6 χ2 df (1), p < 0.01e
Tany,N1-3,M0 50 (52.1%) 32 (30.8%)
Tany,Nany,M1 42 (43.8%) 70 (67.3%)
Smoking status Current smoker 26 (27.1%) 27 (26.0%) χ2 df (2), p = 0.99f
Ex-smoker 41 (42.7%) 45 (43.3%)
Never smoked 9 (9.4%) 9 (8.7%)
Non-smoker (history
NK)
12 (12.5%) 14 (13.5%)
Smoking status NK 8 (8.3%) 9 (8.7%)
ECOGa 0 43 (44.8%) 21 (20.2%) χ2 df (1), p < 0.001g
1 27 (28.1%) 45 (43.3%)
2 <6 18 (17.3%)
Not known 25 (26.0%) 20 (19.2%)
BMIb Mean (SD) 27.60 (4.61) 25.75 (4.69) t-test, p < 0.01
<25 30 (31.3%) 45 (43.3%) χ2 df (2), p = 0.02h
25–29.9 37 (38.5%) 42 (40.4%)
30+ 29 (30.2%) 15 (14.4%)
Site of distant
metastasesc
Lymph (non-pelvic) 27 (64.3%) 40 (57.1%) χ2 df (1), p = 0.46
Bone 12 (28.6%) 20 (28.6%) χ2 df (1), p = 1
Pulmonary/pleura 11 (26.2%) 22 (31.4%) χ2 df (1), p = 0.56
Hepatic 9 (21.4%) 13 (18.6%) χ2 df (1), p = 0.71
aECOG recorded for patients at the first point of receiving treatment with chemotherapy following index date.
bBody mass index (kg/m2 ): measures of 25 and above are considered to exceed healthy weight, with 30 being the threshold for obesity in the UK (19). Data was missing for 2 patients
in the carboplatin-based sub-cohort.
cCategories of distant metastases are not mutually exclusive: patients may have multiple sites. Percentages calculated using denominator of TanyNanyM1.
dComparing bladder and all other sites combined between sub-cohorts.
eComparing TanyNanyM1 and others combined between sub cohorts.
fComparing current smoker, ex-smoker and all others combined between sub-cohorts.
gComparing PS< 2 and PS 2+ between sub-cohorts.
hComparing BMI < 25, 25–29.9 and 30+.
Where data were stratified by platinum treatment status, the
median OS of patients in the cisplatin sub-cohort was 21.0
months (IQR: 13.7, not defined, 95% CI: 16.2–29.6) compared
with 14.6 months (IQR: 9.2, 20.3, 95% CI: 11.6–17.4) for
the carboplatin sub-cohort, suggesting better survival in the
cisplatin treated patients. The 1-year OS post-treatment initiation
estimates were 82.2% (95% CI: 72.9–88.5), and 58.3% (95%
CI: 48.2–67.2) in the cisplatin and carboplatin sub-cohorts,
respectively. The probability of survival remained higher for
the cisplatin sub-cohort up to the 5 years for which OS was
estimated (Figure 2).
A Cox PH model was constructed to estimate comparative
overall survival for the two platinum groups adjusted for
binary categorical variables age (<70 years, 70+yrs), sex (male,
female), confirmed metastasis (TNM0, TNM1) and performance
score (PS < 2, PS = 2+). These covariates were considered
to be predictors of survival and, with the exception of sex,
were significantly differentially distributed between the groups.
There were 145 patients available for analysis once missing
covariates were excluded, and 18.6% (n = 27) patients were
censored. In the combined model, age (Wald χ2 p = 0.58)
and sex (Wald χ2 p = 0.74) were not significant contributors
but treatment group, PS < 2 and metastatic status (TNM1)
were (Wald χ2 p < 0.05). Once OS was adjusted for
differences in age, sex, PS, and metastatic status between the
platinum sub-cohorts, HR for survival in patients treated with
cisplatin was 0.52 (p < 0.01) relative to patients treated with
carboplatin (Figure 3).
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Selected Adverse Events Analysis
Blood tests to identify hematological and hepatic treatment-
related adverse events (AE) were available for 98.0% (n = 196)
of the platinum-treated sub-cohort. The distribution of events
was similar between cisplatin-based and carboplatin-based sub-
cohorts, with neutropenia representing the most common grade
3 or 4 AE observed in both sub-cohorts (Figure 4). Severity
of recorded events tended to be higher in the carboplatin
sub-cohort.
TABLE 4 | First-line (1L) response rates by type of therapy.
All 1L LoT
(n = 216)
1L Cisplatin
sub-cohort
(n = 96)
1L
Carboplatin
sub-cohort
(n = 104)
χ
2 df(1)
comparing
sub-cohorts
Overall Response
Rate
51.9% 64.6% 43.3%
Disease Control
Rate
62.5% 75.0% 53.8%
Complete
response
16 (7.4%) 12 (12.5%) <6 p = 0.03
Partial response 96 (44.4%) 50 (52.1%) 41 (39.4%) p = 0.08
Stable disease 23 (10.6%) 10 (10.4%) 11 (10.6%) p = 0.92
Progressive
disease
57 (26.4%) 15 (15.6%) 36 (34.6%) p < 0.01
Response
missing
24 (11.1%) 9 (9.4%) 12 (11.5%)
OS Median
(95% CI) (months)
16.2
(14.6–18.7)
21.0
(16.2–29.6)
14.6
(11.6–17.4)
PFS Median
(95% CI) (months)
7.6 (6.8–8.7) 10.3 (8.8–12.4) 5.9 (4.6–7.3)
DISCUSSION
To our knowledge, this is the largest UK-based study looking
at real-world outcomes in patients with locally advanced
or metastatic urothelial cancer receiving chemotherapy. We
examined all patients receiving at least one line of chemotherapy.
Just over half (57%) of patients had metastatic (M1) disease at the
time of starting chemotherapy. Platinum-based chemotherapy
formed the mainstay of first-line treatment, with an almost equal
split between those receiving cisplatin- and carboplatin-based
regimens (44 vs. 48%). It is of note that a small number of
patients (treated before 2010) received single agent paclitaxel or
gemcitabine as their first-line of therapy, reflecting a subgroup of
patients of older age and poorer PS. Limited data exists to support
the use of paclitaxel as a single agent in this setting. A small study
of 26 patients reported a response rate of 42% (20), but whether
patients deemed unfit for carboplatin would be best served by
supportive measures alone, or in the future with a CPI, remains
to be established.
Patients receiving a carboplatin-based regimen were older,
more likely to have M1 disease and be of poorer PS than
those receiving cisplatin-based treatment. Almost one in five
patients receiving carboplatin in our cohort were PS2 or 3.
We did not document the reasons for choice of carboplatin
over cisplatin in good performance patients but presumably this
reflects inadequate renal function in most cases. The almost 50%
of patients not receiving a cisplatin-containing regimen in our
study is in line with previous reports (21, 22).
The activity of platinum-based chemotherapy was confirmed
in our study. We estimated an overall response rate of 64.6
and 43.3% in patients receiving cisplatin and carboplatin-based
chemotherapy, respectively. This compares with clinical trial
FIGURE 1 | Sequence of line of therapy for patients treated with first-line platinum-based regimens. The first three lines of treatment are shown only, split by cisplatin
and carboplatin sub-cohorts. Treatments follow sequentially from inner (Line1) to outer (Line3) segments. Blank segments signify no further treatment recorded.
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FIGURE 2 | Overall survival following first diagnosis of advanced or metastatic disease for whole study cohort, and by platinum chemotherapy sub-cohort. Ninety five
percentage confidence intervals for each platinum sub-cohort are shown by dotted lines.
reported ORR of 49.4% for cisplatin plus gemcitabine (5)
and 41.2% with carboplatin plus gemcitabine (23). The lower
response rate associated with carboplatin is consistent with its
known inferiority to cisplatin (7). Interpretation of CT reports
was performed by an experienced oncologist in our study, but
we acknowledge that its retrospective nature may have resulted
in an over-estimation of response rates according to RECIST
criteria (24).
Overall, median survival of patients in our cohort was 16.2
months. Patients receiving cisplatin-based chemotherapy had a
favorable outcome compared to those treated with carboplatin,
and this persisted when adjusted for PS, confirmed metastatic
status, age and sex. Fisher et al. recently reported median OS of
14.6 months with cisplatin and 11.3 months with carboplatin,
in a real-world US setting (25). A 16.1 month median OS was
reported in a retrospective German study of patients with stage
IV UC treated with chemotherapy (26). Whilst the proportion
of M1 patients varied between studies, overall our survival is
remarkably similar and highlights the need to improve outcomes
for this group of patients.
Only a quarter of patients went on to receive second-
line chemotherapy. Just under half of these patients received
single-agent weekly paclitaxel. The low uptake of second-line
therapy, consistent with previous reports (26), may in part
reflect the low response rates and short duration of response
associated with these agents (27). Second-line chemotherapy at
our center has typically been reserved for fit patients or those
with symptomatic disease progression and following careful
FIGURE 3 | Cox regression analysis comparing cisplatin-based (blue) and
carboplatin-based (red) sub-cohorts, adjusted for age, sex, PS, and confirmed
metastasis. One hundred and forty five patients remained after patients with
missing covariates were excluded.
discussions around risks vs. benefit. Given the recent approvals
of both atezolizumab (28) and pembrolizumab (29) following
platinum failure, the proportion of patients treated second-line
could be expected to increase in future, but none of the reported
cohort received these therapies.
We assessed first-line chemotherapy associated adverse event
incidence in terms of hematological and hepatic toxicity.
Incidence of grade 4 neutropenia associated with cisplatin and
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FIGURE 4 | Adverse events recorded for study cohort by common terminology criteria for adverse events (CTCAE) grade of severity and by platinum sub-cohort.
Numbers tested: blood disorders (n = 192), liver disorders (n = 196). Cis, cisplatin sub-cohort; carbo, carboplatin sub-cohort; ALT, alanine aminotransferase; AST,
aspartate aminotransferase; ALK, alkaline.
carboplatin were 17 and 28%, respectively. This is comparable
with rates of 29.9% and 20% in phase III trials of gemcitabine plus
cisplatin (5, 30) and 20.3% for gemcitabine plus carboplatin (23).
Thus, severe neutropenia rates do not appear to be significantly
increased in a real-world setting.
The upper quartile range of age for this cohort was 72–83
years. As the population ages, learning how to optimally assess
and manage elderly patients will become increasingly important.
We did not collect data on patients who received best supportive
care alone and we therefore cannot assess the reasons for this and
the demographics of such patients. This remains a critical area
for future research (21). There are both strengths and limitations
to this study. Extraction of patient data using electronic case
note review was enhanced by an experienced medical oncologist
who undertook clinical review of unstructured patient notes
to maximize data completeness. The number of patients with
missing data was minimal for a study of this kind and mostly
related to missing PS. The inclusion of adverse events is again
not typical and further enhances the dataset. The limitations
come from the retrospective nature of the study and the lack of
inclusion of patients not receiving systemic treatment. The study
design also did not include the collection of surgical procedures.
Thus, the influence on survival outcomes of the small number of
patients who may have undergone radical cystectomy or radical
nephroureterectomy following a response to chemotherapy has
not been documented.
In summary, we provide a real-world view of treatment
and outcomes in the pre-immunotherapy era for patients with
advanced or metastatic UC receiving chemotherapy in a UK
setting. The poor outcomes seen in our study reflect those
observed both in clinical trials and other recent real-world
studies and reinforce the fact that survival has remained static
in the pre-immunotherapy era. As CPI become increasingly
incorporated into routine clinical care, the data presented here
will provide an important benchmark to allow the impact of
these and other novel therapeutic strategies to be evaluated in
the future.
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